SCHEMBL4510316

SCHEMBL4510316

C[C@@H](COc1cccc2cnccc12)NS(=O)(=O)c1cc(Cl)sc1Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 11/20 0.68
PRKD3 O94806 3/20 0.41
PRKCG P05129 3/20 0.41
PRKCB P05771 3/20 0.41
PRKCA P17252 3/20 0.41
PRKCH P24723 3/20 0.41
PRKCI P41743 3/20 0.41
PRKCE Q02156 3/20 0.41
PRKCQ Q04759 3/20 0.41
PRKCZ Q05513 3/20 0.41
PRKCD Q05655 3/20 0.41
PRKD1 Q15139 3/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
NFKB1 P19838 2/20 0.41
GLA P06280 1/20 0.41
LMNA P02545 2/20 0.40
PMP22 Q01453 1/20 0.40
PRKACA P17612 3/20 0.39
PRKACG P22612 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4513381 0.85 NR3C1 (0.64) NR3C1PRKD3PRKCGPRKCBPRKCA
SCHEMBL4512184 0.84 NR3C1 (0.72) NR3C1PRKD3PRKCGPRKCBPRKCA
SCHEMBL4501569 0.83 NR3C1 (0.68) NR3C1LMNAMEN1KMT2ATP53
SCHEMBL4506694 0.81 NR3C1 (0.85) NR3C1PRKD3PRKCGPRKCBPRKCA
SCHEMBL4512135 0.81 NR3C1 (1.00) NR3C1PRKD3PRKCGPRKCBPRKCA
SCHEMBL4508287 0.80 NR3C1 (0.72) NR3C1PRKD3PRKCGPRKCBPRKCA
SCHEMBL4520415 0.79 NR3C1 (1.00) NR3C1
SCHEMBL4522810 0.79 NR3C1 (0.66) NR3C1PRKD3PRKCGPRKCBPRKCA
SCHEMBL4512055 0.78 NR3C1 (0.74) NR3C1KCNA3
SCHEMBL4512972 0.76 NR3C1 (0.66) NR3C1PRKD3PRKCGPRKCBPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 NR3C1 1/4885PRKD3 2927/4885PRKCG 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.